AVXL granted patent protection until 2036, plus possible extensions, for the crystal form of blarcamesine (what we know as 2-73). This "is exceptionally important.... because all clinical trials with Anavex 2-73.... are using the patent protected crystal forms as the active pharmaceutical ingredient."